Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 494.50% and ...

Scorpion’s drug candidate inhibits a mutation that is a major driver of breast, gynaecological and head and neck cancers ...

Johnson & Johnson stock (NYSE: JNJ) lost about 7% in 2024, underperforming the broader S&P 500 index, which gained 23% for ...

Eli Lilly in talks to acquire cancer biotech Scorpion Therapeutics for $2.5 billion, with potential milestone payments.

Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for ...

Nuvalent's NVL-655 and Zidesamtinib show strong potential as first-line therapies for NSCLC. Click here to find out why I ...

FDA's Center for Drug Evaluation and Research director, Patrizia Cavazzoni, MD, to step down in mid-January. Other top leaders also leaving FDA.

Startup Virta Health saw 60% revenue growth last year, topping $100 million, driven by demand for its employer weight loss ...

Venture capital firm Andreessen Horowitz said on Friday it was working with Eli Lilly to launch a $500 million venture fund that will be fully funded by the U.S. drugmaker.

Eli Lilly and venture capital firm Andreessen Horowitz (a16z) are joining forces to create a unique new fund dubbed the ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Eli Lilly has been operating a global capability center (GCC) in Bengaluru, India. | For nearly a decade, Eli Lilly has been operating a global capability center (GCC) in Bengaluru, India. Now, with ...